Neurotech companies sit on incredible stories but bury them in whitepapers nobody reads. We build content engines that educate your market, shorten your sales cycle, and position you as the obvious choice — without dumbing down the science.
The Problem
Your content reads like a journal submission, not a sales tool
Neurotech teams default to writing for peer review because that's what they know. The result is content that impresses other PhDs but does nothing for the VP of Procurement at a hospital system or the partner at a healthtech fund. You're producing content, but it's not producing pipeline. The gap between your technical depth and your buyer's reading habits is where deals go to die.
Long sales cycles with no content to nurture prospects through them
Neurotech sales cycles run 12-18 months or longer, especially for medical devices. During that time, your prospect is evaluating alternatives, building internal consensus, and navigating their own procurement process. Without a content strategy designed for that timeline, you're relying entirely on your sales team to keep deals warm. That's expensive and doesn't scale.
You can't talk about clinical results the way you want to
FDA regulations and legal review create real constraints on what neurotech companies can say publicly about their products. Most marketing teams either avoid clinical content entirely — leaving their best stories untold — or push something through legal review that's been edited into meaninglessness. Neither approach works. You need content frameworks that satisfy regulatory requirements while still being compelling to read.
Your competitors are building thought leadership while you stay quiet
The neurotech companies winning mindshare aren't necessarily the ones with the best technology. They're the ones consistently publishing insights that make investors and buyers smarter. Every month you're not producing category-level content, a competitor is filling that space. In a market where trust and credibility are everything, silence is a strategic liability.
How We Help
We start by mapping your content to your actual sales process. Most neurotech companies have content scattered across their website, investor materials, and conference presentations with no connective tissue. We audit everything you've published, interview your sales team about what questions they hear most, and identify the gaps in your buyer's journey where content should be doing the work your sales reps are currently doing manually.
From the audit, we build an editorial strategy organized around the questions your buyers actually ask — not the topics your team wants to write about. For neurotech, this usually means a mix of clinical education content, regulatory milestone narratives, market sizing and trends pieces, and technical differentiation content. Each piece has a defined audience, a stage in the buying process, and a measurable goal.
We then build the production system. Neurotech content requires subject matter expertise, which means your technical team has to be involved. But they shouldn't be writing 2,000-word blog posts. We use a structured interview and extraction process that takes 30 minutes of a scientist's time and turns it into a polished piece that's technically accurate and actually readable. Your team contributes knowledge; we handle everything else.
Regulatory compliance is built into the workflow, not bolted on after. We develop content templates with pre-approved language frameworks for different claim levels. Your legal team reviews the framework once, and then individual pieces move through faster because they're built on approved structures. This is critical for neurotech companies where a single off-label claim can create serious problems.
Distribution is half the strategy. We build channel-specific content plans for LinkedIn, email nurture sequences, conference follow-ups, and sales enablement. Each piece gets repurposed across formats — a long-form article becomes a LinkedIn series, an email drip, and a sales one-pager. Neurotech audiences are concentrated in specific channels and communities, so we focus distribution where your buyers actually spend time.
Measurement ties everything back to pipeline. We track content engagement, but more importantly, we track content influence on deals. Which pieces are being shared in sales cycles? Which blog posts correlate with demo requests? What email content moves prospects to the next stage? This data shapes the editorial calendar on a rolling basis.
The engagement includes a 90-day sprint to build the foundation — strategy, first content batch, and distribution infrastructure — followed by an ongoing production cadence. Most neurotech clients run 4-8 pieces per month across formats once the engine is built.
What we deliver
- Content strategy — editorial calendar, audience mapping, buyer journey alignment, and regulatory-compliant content frameworks
- Monthly content production — 4-8 pieces per month including articles, case narratives, email sequences, and sales enablement materials
- Distribution playbook — channel strategy, repurposing workflows, and audience-specific distribution plans
- Performance dashboard — content engagement, pipeline influence tracking, and monthly optimization recommendations
The best neurotech content doesn't simplify the science — it contextualizes it. Your buyers aren't stupid; they're busy. Give them the clinical story in a format they can absorb in five minutes and share with their internal stakeholders, and you'll win deals your competitors didn't even know were in play.
Our Methodology
Our 90-day sprint builds the entire content engine. Days 1-30 are strategy: content audit, stakeholder interviews, buyer journey mapping, and editorial calendar development. We also establish the regulatory review framework during this phase so it doesn't become a bottleneck later. By day 30, you have a documented strategy and the first content briefs in production.
Days 31-60 are production ramp. We publish the first batch of content, test distribution channels, and refine the subject matter expert extraction process with your team. This is where we learn what resonates with your specific audience and adjust the strategy based on real data rather than assumptions.
Days 61-90 are optimization and handoff to steady state. The content engine is running, distribution channels are proven, and measurement is in place. We transition from building the system to operating it. Clients typically continue with ongoing monthly production after the sprint, but the strategic foundation is complete and your team could run it independently if needed.
How We Work
The first 90 days require a dedicated content strategist and writer from our side, plus a production manager who coordinates with your subject matter experts and legal team. Your time commitment is roughly 2-3 hours per week from your technical team for knowledge extraction, plus legal review cycles on new content types.
After the sprint, ongoing engagements run on a monthly cadence with an editorial planning session at the start of each month, weekly content reviews, and monthly performance readouts. We adjust the editorial calendar based on what's working, what your sales team needs, and any regulatory milestones or market events that create content opportunities.
The team structure scales with your needs. A typical neurotech content engagement involves a strategist, a writer with healthcare or science communication experience, and a distribution specialist. For companies with active clinical programs, we sometimes add a medical writer who understands peer-reviewed evidence hierarchies.
Clients should expect a content engine that produces measurable pipeline impact within two quarters. The first quarter builds the foundation and starts generating early engagement data. The second quarter is where you see content showing up in sales conversations and influencing deal progression.
- Consistent content production that maintains technical accuracy while reaching non-technical decision-makers
- Shorter sales cycles through content that educates and nurtures prospects without manual sales effort
- Category thought leadership that builds trust with investors, buyers, and clinical partners
If your neurotech company needs content marketing leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does content marketing cost for neurotech companies?
The 90-day sprint typically runs $50K-$100K depending on volume and complexity. Ongoing monthly production ranges from $15K-$40K per month based on how many pieces you need and the level of technical depth required. For comparison, a single conference sponsorship can cost $50K and generate a fraction of the long-term pipeline value that a year of consistent content produces.
How long before we see results from content marketing?
You'll have content publishing within 45 days. Engagement metrics show up immediately — traffic, shares, email opens. Pipeline influence takes longer to measure, typically 3-6 months, because neurotech sales cycles are long. The content you publish in month one is still working deals in month nine. That compounding effect is the whole point.
How does the content marketing team integrate with our existing staff?
We need access to your subject matter experts for 30-minute knowledge extraction sessions, usually 2-3 per month. We handle all writing, editing, design, and distribution. Your legal or regulatory team reviews content using a pre-approved framework that speeds up the process. We integrate into your existing communication tools and work like an embedded team, not an outside vendor.
What makes Winston Francois different from a traditional content marketing agency?
Most content agencies don't know the difference between a BCI and an EEG headband. We build content for complex, regulated industries where getting the science wrong isn't just embarrassing — it's a compliance risk. Our process is built to extract knowledge from technical teams efficiently and produce content that passes both regulatory review and the 'would I actually read this' test.
How do you measure ROI from a content marketing engagement?
We track two layers. Surface metrics: traffic, engagement, email performance, and social reach. Pipeline metrics: content-influenced deals, content touches in closed-won opportunities, sales cycle length for content-engaged versus non-engaged prospects, and inbound lead quality. We set up attribution in your CRM so you can see exactly which content is contributing to revenue.
What type of neurotech company is the right fit for this service?
Companies with a product in market or approaching commercialization get the most from content marketing. You need something to sell and a buyer to educate. If you're pre-clinical with no commercial timeline, content can still support fundraising, but the scope is different. The ideal client has at least one defined buyer persona, a sales team (even if it's just the founder), and clinical or technical differentiation worth talking about.
